| Strategic collaborations
are an important element of Exoxemis’ business strategy, balancing
continual independent research and product development with revenues from
product partnering and technology licensing. The unique characteristics
of the MPO and EPO technology platform — rapid cidal action, broad-spectrum
activity, and unique mechanism of action — are particularly well-suited
for prevention and treatment of serious infections and a variety of other
medical, veterinary, agricultural, and industrial areas.
Bringing new products to market
We leverage our scientific expertise, intellectual property and capital,
and proprietary know-how to help bring new products to market. In addition
to offering state-of-the-art capabilities, we also support academic investigators
to help accelerate research and discovery.
We welcome strategic alliances to integrate our technology with the intellectual,
financial, and commercial strengths of prospective partners to bring significant
new products to market. Interested parties should contact
us to discuss licensing and partnering opportunities.
|
